Cerevance utilizes its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify novel therapeutic targets for neurological diseases, including Parkinson's and Alzheimer's. The company develops cell type-specific therapies aimed at addressing the unmet medical needs associated with neurodegenerative and psychiatric disorders.
Funding
$214M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DPFounders
Product
Problem
Current treatments for neurological diseases like Parkinson's and Alzheimer's often lack specificity, failing to address the underlying cellular mechanisms within the central nervous system. This can lead to limited efficacy and unwanted side effects due to the broad impact on various brain cell types.
Solution
Cerevance leverages its Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to discover and develop novel, cell type-specific therapeutic targets for neurological and psychiatric disorders. NETSseq provides a detailed understanding of the complexities within the human brain, enabling the identification of differentiated product candidates. The company focuses on advancing potential first-in-class programs, including both small molecules and biologics, that can selectively modulate specific neuronal populations affected by disease. Cerevance's approach aims to create more effective and targeted treatments, addressing unmet medical needs associated with neurodegenerative and psychiatric conditions while minimizing off-target effects.
Target Audience
Cerevance's primary target audience includes pharmaceutical companies, research institutions, and clinicians focused on developing and utilizing targeted therapies for neurological and psychiatric disorders.
Features
- NETSseq platform for identifying novel drug targets based on human brain tissue analysis
- Focus on cell type-specific therapies for precision targeting of disease mechanisms
- Pipeline of differentiated product candidates for neurodegenerative, psychiatric, and CNS-controlled metabolic disorders
- CVN424, a non-dopaminergic therapy for Parkinson's disease, currently in Phase 2 clinical trials
- CVN293, a selective KCNK13 inhibitor for neuroinflammation-driven diseases like ALS and Alzheimer's, currently in Phase 1 clinical trials
- CVN766, a selective orexin 1 receptor antagonist for schizophrenia, with completed Phase 1 clinical trials
- Strategic research collaboration with Merck for the discovery of novel targets in Alzheimer's disease